Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Every year thousands of pilgrims visit religious sites in the mountains of Nepal, many of them unaware of the dangers of climbing to high altitudes. The Himalayan Rescue Association, OUCRU Public Engagement and Media for Development worked together with the pilgrim community to create a public health film to inform others of the challenges of these journeys.

In August 2016 Media for Development worked with 12 young people from Bhaktapur in Kathmandu to film the Gosainkunda pilgrimage. The Gosainkunda Lake lies at an altitude of 4380 meters above sea level and is considered holy by Buddhist and Hindus in Nepal. A festival lasting two to three days takes place here every year and is attended by up to 20,000 pilgrims. A desolate place for most times of the year, it becomes a teeming hub where pilgrims from right across the country gather to bathe and pray at the lake. Many pilgrims are ill prepared, ascend too quickly and suffer from altitude related illnesses.

Filming their own experiences and interviewing others on the pilgrimage or at the local rest stops, the group created a film which explains the perils of the mountains and how to be better prepared.  In 2017, Himalayan Rescue Association, Media for Development and some of the participants toured around Kathmandu holding community screenings of the film and offering advice to those considering the pilgrimage.

This project was led by Dinesh Deokota (Media for Development), Buddha Basynat (OUCRU-Nepal and Himalayan Rescue Association) and Mary Chambers (Head of Public Engagement at OUCRU).  The project was funded by a Wellcome Trust International Engagement Award.

Find out more: Buddha Basnyat interview on High altitude illness

Similar stories

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.

World’s largest clinical trial for COVID-19 treatments expands internationally

EOCRU OCGHR OUCRU Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.